Beovu vs. Lucentis

Beovu (brolucizumab-dbll) Injection and Lucentis (ranibizumab) Injection are used to treat Neovascular (Wet) Age-Related Macular Degeneration (AMD).

Beovu and Lucentis belong to different drug classes. Beovu is a human vascular endothelial growth factor (VEGF) inhibitor and Lucentis is a monoclonal antibody.

Side effects of Beovu and Lucentis that are similar include blurred vision.

Side effects of Beovu that are different from Lucentis include cataracts, bleeding in the eye, eye pain, and eye "floaters."

Side effects of Lucentis that are different from Beovu include discomfort and increased tears in the affected eye(s), itchy or watery eyes, dry eyes, swelling of the eyelids, sinus pain, sore throat, cough, and joint pain.

Both Beovu and Lucentis may interact with other drugs.

Common side effects of Beovu include:

• blurred vision,
• cataracts,
• bleeding in the eye,
• eye pain, and
• eye "floaters"

Common side effects of Lucentis include:

• discomfort and increased tears in the affected eye(s),
• itchy or watery eyes,
• dry eyes,
• swelling of the eyelids,
• blurred vision,
• sinus pain,
• sore throat,
• cough, or
• joint pain.

Lucentis may infrequently increase your risk for developing a certain serious eye condition (endophthalmitis), especially during the first week after receiving a dose. Tell your doctor if you notice symptoms in the affected eye(s) such as pain, redness, sensitivity to light, or a sudden change in vision.

Beovu (brolucizumab-dbll) Injection is a human vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of Neovascular (Wet) Age-Related Macular Degeneration (AMD).

Lucentis (ranibizumab) Injection is a monoclonal antibody that works by slowing the growth of abnormal new blood vessels in the eye and decreasing leakage from these blood vessels used to treat the wet form of age-related macular degeneration.

Beovu may interact with other drugs. Tell your doctor all medications and supplements you use.

zOther drugs may interact with Lucentis. Tell your doctor all prescription and over-the-counter medications and supplements you use.

Beovu is administered by intravitreal injection. The recommended dose for Beovu is 6 mg (0.05 mL of 120 mg/mL solution) monthly (approximately every 25-31 days) for the first three doses, followed by one dose of 6 mg (0.05 mL) every 8-12 weeks.

Lucentis is administered as an injection into the eye, with local anesthetic. It is done under physician supervision. Dose is 0.5 mg (0.05 mL) and is administered once a month.